Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)
Can-Fite BioPharma Ltd. (TASE:CFBI) has begun Phase II clinical trials for its CF101 drug for the treatment of symptoms of keratitis sicca (dry-eye syndrome).
The test will be conducted in Israel among 50 patients who will receive CF101 over 12 weeks at four medical centers.
The results of the trial will also be sent to the US Food and Drug Administration (FDA). If CF101 is shown to be effective, Can-Fite can apply for orphan drug status, which if approved, will greatly speed up its development.
Dry eye syndrome commonly affects wearers of contact lenses, women going through menopause, and is a side effect of rheumatoid arthritis. Figures published indicate that the over six million people in the US alone suffer from dry eye syndrome, and the market for treatments is estimated at $1 billion a year.
Source: Globes [online], Israel business news - www.globes.co.il - on January 28, 2007
Filed under Dry Eyes, Eye Treatment
You may also like to read
- Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III Trial
- Post-Lasik Near Vision Treatment With Conductive Keratoplasty Trial Underway
- Beware of Computer Vision Syndrome
- Fusarium Keratitis: General Information And Awareness
- Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular Degeneration
- Phase II Clinical Trial of Mifepristone an Eye Drop Treatment for Steroid Associated Elevated Intraocular Pressure
- Axial Myopia May be Treated By Hydrogel
- Dry Eye Treatment by Omega Fatty Acids in Combination with Artificial Tears
- Progesterone can Effectively Treat Dry Eye Syndrome
- Dry Eye Syndrome in Women May be Prevented by Regulating Fatty Acid Intake
